Notice to MRNA Shareholders: Robbins LLP reminds investors of the class action lawsuit filed against Moderna, Inc.

Robbins LLP reminds investors that a shareholder has filed a class action lawsuit on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune diseases, and cardiovascular diseases in the U.S., Europe and internationally.

For more information, please submit a form, email attorney Aaron Dumas, Jr., or call us at (800) 350-6003.